Startseite Kongressberichte & Archiv ESMO World Congress on Gastrointestinal Cancer Session VII: Gastric Cancer - Presentation of Selected Abstracts

Session VII: Gastric Cancer - Presentation of Selected Abstracts

The conclusion from authors abstract:
Pembrolizumab significantly improved OS vs chemotherapy as second-line therapy for advanced esophageal cancer with PD-L1 CPS ≥10, with a more favorable safety profile and stable and similar QOL. These data support pembrolizumab as a new second-line standard of care for esophageal cancer with PD-L1 CPS ≥10.

LBA-002: Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
Josep Tabernero, et al.
The conclusion from authors abstract:
As 1L therapy for advanced GC, P was noninferior to C for OS in CPS ≥1 with clinically meaningful improvement for OS in CPS ≥10. P+C did not show superior OS and PFS in CPS ≥1 and OS in CPS ≥10. The safety profile was more favorable for P vs C.

LBA-003: A phase III study of TAS-118 plus Oxaliplatin versus S-1 plus Cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study)
Yoon-Koo Kang, et al.
The conclusion from authors abstract:
TAS-118 plus oxaliplatin improved survival compared to SP in pts with AGC. Non-hematological toxicities of TAS-118 plus oxaliplatin were greater but manageable. TAS-118 plus oxaliplatin can be a new standard first-line chemotherapy for AGC.
 
Remembering the TAGS Study, which was presented last year at ESMO-GI:
 
 
 
See comments about the TAGS-Study from Eric Van Cutsem, Josep Tabernero and Julien Taieb given at this years ESMO-GI: